Puma Biotechnology

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results. This addition aims to improve treatment options for recurrent or metastatic disease.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib for HER2-mutated tumors. This addition is based on the Phase II SUMMIT trial results, offering neratinib as a second-line therapy option for patients with HER2-mutated recurrent or metastatic cervical cancer.

Puma Biotechnology announced NCCN updated cervical cancer guidelines to include neratinib monotherapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

Puma Biotechnology announced NERLYNX® inclusion in NCCN Cervical Cancer Guidelines as a second-line therapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

XTX Topco Ltd reduced its stake in Puma Biotechnology by 45.7% in Q3. Several institutional investors adjusted their holdings in Puma Biotechnology in Q2. Puma Biotechnology's stock opened at $2.75 on Friday, with a market cap of $134.99M. The company reported $0.41 EPS for Q3, surpassing estimates. StockNews.com downgraded Puma Biotechnology from 'strong-buy' to 'buy'. Puma Biotechnology focuses on cancer care products, including NERLYNX.

Fmr LLC increased its stake in Puma Biotechnology by 27.1% in Q3, owning 118,265 shares worth $302,000. Several institutional investors also boosted their holdings. PBYI stock opened at $2.75, with a market cap of $134.99M. The company reported $0.41 EPS for Q3, surpassing estimates. HC Wainwright maintained a 'buy' rating with a $7.00 target price.

The biotech industry is growing rapidly due to advancements in genomic research, personalized medicine, and innovative platforms, with key stocks like HRMY, TRDA, and PBYI leading the charge. The global biotechnology market is projected to reach $4.61 trillion by 2034, driven by increased investment, favorable regulations, and high demand for novel therapies. TRDA specializes in EEV therapeutics for neuromuscular diseases, HRMY focuses on rare and neurological diseases, and PBYI develops cancer treatments, all showing strong financials and growth potential.

Puma Biotechnology granted a 7,500-share restricted stock unit award to a new non-executive employee on Dec 2, 2024, under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with vesting conditions tied to continued employment.